A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment

The information about chronic myeloid leukemia (CML) patients with a deep molecular response of ≥ 4.5 log reduction (MR4.5) in whom the dose of imatinib (IM) had to be reduced to relieve toxicity is insufficient. In 205 CML patients the dose of IM was reduced in 19 (31.2%) out of 61 patients with MR4.5. The patients (12 pretreated with interferon-alpha) achieved MR4.5 after an average of 27.7 months. The duration of MR4.5 before the reduction of the dose was 16–123 (mean = 56.7) months. After the IM reduction (200 mg daily to 400 mg twice weekly for 15–90 (mean = 48) months) MR4.5 or major molecular response (MMR) was maintained in 14 (73.7%) and 2 (10.5%) patients, respectively. Three patients who lost MMR (15.8%) after the discontinuation of IM regained MR4.5 after the reintroduction of a lower dose. A lower dosage of IM should be tested for the management of side effects in patients with MR4.5 in prospective studies.

[1]  Max E Valentinuzzi,et al.  SAFETY AND EFFICACY , 2010 .

[2]  E. Basch,et al.  The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events , 2018, Journal of Patient-Reported Outcomes.

[3]  J. Apperley.  TWIST it but don't spin it. , 2013, Blood.

[4]  M. Jarošová,et al.  Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia. , 2012, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[5]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[6]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Egorin,et al.  Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing , 2006, Leukemia & lymphoma.

[8]  M. Breccia,et al.  Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. , 2013, Leukemia research.

[9]  Francisco Cervantes,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .

[10]  T. Kyo,et al.  Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib , 2012, British journal of haematology.

[11]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[12]  C. Cleeland,et al.  Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. , 2013, Blood.

[13]  M. Jarošová,et al.  Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting , 2012, Annals of Hematology.

[14]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[15]  J. Melo,et al.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. , 2013, Blood.

[16]  E. Faber.  Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia? , 2009, Leukemia research.

[17]  T. Porter.  Measuring What? , 2012 .